Agios Appoints Jonathan Biller as Chief Legal Officer
November 25 2019 - 7:00AM
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of
cellular metabolism to treat cancer and rare genetic diseases,
today announced the appointment of Jonathan Biller to the newly
created role of chief legal officer effective December 3, 2019.
Prior to Agios, Mr. Biller served as executive vice president,
general counsel at Celgene Corporation.
“With 30 years of broad legal, tax and treasury experience,
Jonathan is an excellent addition to our leadership team during
this time of growth at Agios,” said Jackie Fouse, Ph.D., chief
executive officer of Agios. “In particular, his expertise with
international legal matters and business development will be
instrumental as we continue to deliver on value-creating
milestones.”
Mr. Biller served as executive vice president, general counsel
at Celgene from July 2018 to November 2019 where he was responsible
for Celgene’s global legal function. He joined Celgene in 2011,
serving as senior vice president, tax and treasury, responsible for
Celgene’s global tax and treasury functions including the company’s
capital allocation strategy and tax policy. Prior to Celgene, Mr.
Biller was general counsel, chief tax officer and secretary, from
2008 to 2011 at Bunge Limited, a publicly traded agriculture and
food company. Prior to Bunge, Mr. Biller held roles of increasing
responsibility at Alcon, Inc. during which time it was a publicly
traded company. He began his legal career at Hopkins & Sutter
rising to the level of partner and was also partner at Foley &
Lardner after the firms merged. Mr. Biller also serves on the Board
of Junior Achievement New Jersey. He holds a B.A. degree from Brown
University and a J.D. from Yale Law School.
“I have great admiration for Agios’s accomplishments over the
past 10 years,” said Mr. Biller. “I am thrilled to join this
growing team with a shared commitment to fostering a culture of
energy, passion and desire to bring out the best in each other in
pursuit of great science that will benefit patients.”
About Agios Agios is focused on discovering and
developing novel investigational medicines to treat cancer and rare
genetic diseases through scientific leadership in the field of
cellular metabolism and adjacent areas of biology. In addition to
an active research and discovery pipeline across both therapeutic
areas, Agios has two approved oncology precision medicines and
multiple first-in-class investigational therapies in clinical
and/or preclinical development. All Agios programs focus on
genetically identified patient populations, leveraging our
knowledge of metabolism, biology and genomics. For more
information, please visit the company's website
at www.agios.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding the expected benefits of Mr. Biller’s employment and
Agios’ strategic plans and focus. The words "expects,"
"anticipates," "believes," "intends," "estimates," "plans," "will,"
"outlook" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from Agios'
current expectations and beliefs. For example, there can be no
guarantee that any product candidate Agios is developing will
successfully commence or complete necessary preclinical and
clinical development phases, that development of any of Agios'
product candidates will successfully continue, or that any positive
developments in Agios' business will result in stock price
appreciation. Management's expectations and, therefore, any
forward-looking statements in this press release could also be
affected by risks and uncertainties relating to a number of other
important factors, including: Agios' results of clinical trials and
preclinical studies, including subsequent analysis of existing data
and new data received from ongoing and future studies; the content
and timing of decisions made by the U.S. FDA and other
regulatory authorities, investigational review boards at clinical
trial sites and publication review bodies; Agios' ability to obtain
and maintain requisite regulatory approvals and to enroll patients
in its planned clinical trials; unplanned cash requirements and
expenditures; competitive factors; Agios' ability to obtain,
maintain and enforce patent and other intellectual property
protection for any product candidates it is developing; Agios'
ability to maintain key collaborations; and general economic and
market conditions. These and other risks are described in greater
detail under the caption "Risk Factors" included in Agios’ public
filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Agios expressly disclaims any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Investor & Media ContactHolly Manning,
617-844-6630Associate Director, Investor
RelationsHolly.Manning@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Sep 2023 to Sep 2024